Ads
related to: multiple myeloma- Primary and Subgroup Data
Primary- and Subgroup-
Specific Data
- Phase 3 Trial
Explore the Phase 3 Trial Design,
Results, and Patient Population
- Contact a Representative
For Questions and Information
About This Treatment
- Patient Profile
Potential Treatment Candidates
HCPs, See Who May Be Appropriate
- Primary and Subgroup Data
Search results
Arcellx shares target raised by Stifel on study design By Investing.com
Investing.com· 6 days agoThe adjustment follows the company's announcement regarding the design of a phase 3 study for...
HaemaLogiX welcomes former Australian Federal Minister for Health Professor the Hon Greg Hunt to the...
WPRI Providence· 1 day agoHaemaLogiX Ltd, a clinical stage biotech developing novel immunotherapies for patients with blood cancers and B-cell diseases, is pleased to announce the appointment of Professor the Hon Greg ...
Doubt Cast on MGUS-Autoimmune Disease Link
MedPage Today· 2 days agoContrary to earlier studies, the not-entirely-rare condition known as monoclonal gammopathy of undetermined significance (MGUS) did not appear to raise...
1 million veterans have now received health benefits for toxic exposure through the PACT Act
Stars and Stripes· 12 hours agoThe delivery of benefits to veterans exposed to burn pits and other toxins from military service...
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
KTLA-TV Los Angeles· 4 days agoBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today ...
FDA approves Amgen drug for tough-to-treat form of lung cancer
BioPharma Dive via Yahoo Finance· 4 days agoImdelltra, a bispecific antibody targeting a protein called DLL3, is cleared for use following...
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
InvestorPlace· 1 day agoFundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying...
Telo Genomics, Emery Pharma Ink Collaboration Agreement
GenomeWeb News· 5 days agoThe collaboration will align Telo's telomere 3D structural biomarker-based platform with Emery's biologic drug development expertise.
What Is The New Treatment Instead of Chemotherapy?
San Diego Red via Yahoo News· 7 days agoAmerica has qualified medical personnel to walk you through your cancer journey, but the prices are out-of-this-world. It’s extremely difficult to find...
Earnings call: Autolus Therapeutics Reports Progress and Financials for Q1 2024
Investing.com· 4 days agoIn a recent earnings call, Autolus Therapeutics (NASDAQ: AUTL ), a biopharmaceutical company...
